1. Introduction {#s0005}
===============

*Nigella sativa* (*N. sativa*) is an herb that belongs to the family Ranunculaceae, which has been historically used as medicinal food to treat a wide range of pathological conditions ([@b0020]). Recently, black seed (*N. sativa* seed) has been the subject of extensive medical research to elucidate its biologically active components and to determine its potential therapeutic applications ([@b0020], [@b0075]). It has been shown to enhance learning and memory ([@b0135]) and affect plasma lipids, leading to a lower total cholesterol and triglyceride levels and augmented high-density lipoprotein cholesterol levels ([@b0140]). In addition, *N. sativa* seed has been shown to have immunomodulatory, anti-inflammatory ([@b0120]), cardio-protective, anti-cancer ([@b0150]), anti-oxidant ([@b0055]), anti-sepsis ([@b0035], [@b0040]), hepatoprotective ([@b0015], [@b0115]), nephroprotective ([@b0045], [@b0060]) and anti-diabetic effects ([@b0010], [@b0025], [@b0090]).

Thymoquinone (THQ; 2-Isopropyl-5-methylbenzo-1,4-quinone) [Fig. 1](#f0005){ref-type="fig"} is the most active chemical constituent of the essential oil of black seed and accounts for the majority of its therapeutic properties. We have previously reported the pharmacokinetics of THQ following intravenous (I.V.) and oral (P.O.) administration in a male rabbit model ([@b0030]). Interestingly, gender-dependent pharmacokinetic behaviors of various compounds have been demonstrated in several works ([@b0105], [@b0110], [@b0160], [@b0070], [@b0155]). This could be due to the gender-related variations in body weight, fat tissue distribution, plasma protein binding, metabolizing enzymes and drug transport activities ([@b0065], [@b0050]). Additionally, gender differences in preclinical studies used in the safety assessments of a new chemical entity may offer a rationale for choosing different preliminary doses based on gender to be used in clinical trials. Gastrointestinal simulations based on the Advanced Compartmental Absorption and Transit (ACAT) model have become a vital in silico tool to forecast the *in vivo* drug performance during drug development and quality ratification. The essential character of ACAT model which add to its use in biopharmaceutical drug characterization is that it provides association between formulation performance and drug product pharmacokinetics ([@b0125], [@b0130]). In this study, we evaluated the pharmacokinetic parameters of THQ following I.V. and P.O. dosing in male and female rats to assess the gender effect *in vivo*.Fig. 1Chemical structure of 2-Isopropyl-5-methylbenzo-1,4-quinone (Thymoquinone, THQ).

2. Materials and methods {#s0010}
========================

2.1. Chemicals {#s0015}
--------------

Thymoquinone and internal standard (IS, thymol) were acquired from Sigma-Aldrich (St Louis, USA). Chromatographic grade Methanol was acquired from Panreac Chemicals (Barcelona, Spain) and Potassium dihydrogen phosphate (KH~2~PO~4~) was purchased from Winlab Ltd. (Maidenhead, UK). Distilled water (Mili-Q) was produced in our laboratory. All other chemical reagents used were at of analytical grade.

2.2. Study protocol {#s0020}
-------------------

Twenty-four male and female rats (12 each) weighing 200--220 gm were acquired from the Animal Care and Use Center at College of Pharmacy, King Saud University. The study was approved by the College of Pharmacy Ethical Committee (KSU-SE-19-17). The rats were distributed into four groups (n = 6 animals) for I.V. and P.O. administration. The rats were kept in agreement with the approvals of the "Guide for the Care and Use of Laboratory Animals" of the center. The rats were kept under laboratory conditions of temperature, humidity, 60%; 23 ± 2 °C; and a 12-h/12-h light-dark cycle), with free access to water and food.

Thymoquinone was liquefied in normal saline solution consisting of DMSO (10%). After overnight fasting, THQ was administered in male and female rats through the tail veins (I.V.) at a dose of 5 mg/kg using sterile disposable syringes. For the P.O. dosing, THQ solution was suspended in 10 ml of carboxy methyl cellulose (CMC). This solution was given orally at a dose of 20 mg/kg using a gavage needle. Blood samples (1 ml) were drawn from retro-orbital plexus at the following intervals--immediately before administration and 0.25, 1, 2, 3, 4, 6, 12 and 24 h post P.O. dosing. For the I.V. treatment, the sampling was carried out up to 6 h (i.e., 0.08, 0.25, 0.50, 1, 2, 4 and 6 h). The blood samples were collected in 1 ml anti-coagulant tubes (8 mg of disodium EDTA). Plasma separation was carried out by centrifugation at 5000*g* (Eppendorf, NY, USA) for 10 min, and stored at −80 °C for the quantitative investigation of THQ.

2.3. Preparation of sample and pharmacokinetics {#s0025}
-----------------------------------------------

The concentration of THQ in rat plasma was determined by an HPLC/UV method that has been established and validated in our laboratory ([@b0030]). Briefly, to 200 µl of plasma comprising of THQ, IS 20 µl (20 µg/ml) was added in an eppendorf tube. The mixture was vortexed and then centrifuged at 2500*g* for additional 10 min. The supernatant was removed into a new tube. The sample was dried and reconstituted with 200 µl of mobile phase and 10 µl from of the sample was injected into the HPLC column for THQ analysis.

A non-compartmental pharmacokinetic analysis as previously described by Alkharfy et al. was used to check the pharmacokinetic behavior of THQ in plasma ([@b0030]). The pharmacokinetic analysis was performed using PK Solver software (version 1.0) on the individual plasma concentration-time curves. The calculated parameters were as follows: The elimination rate constant, λz; the apparent half-life, T~1/2~; time to maximum concentration, T~max~; maximum concentration in plasma, C~max~; area under curve, AUC; area under moment curve, AUMC; mean residence time, MRT; volume of distribution, Vz, total clearance; Cl, volume of distribution at steady state, Vss.

2.4. Prediction of the pharmacokinetic profile and model simulation (ACAT Model) {#s0030}
--------------------------------------------------------------------------------

All simulations and predictions were performed using the commercially accessible software GastroPlus version 9.0 (Simulation Plus Inc., CA, USA) fixed with Advanced Compartmental Absorption Transit (ACAT). The input parameters required to run the simulation were extracted from literature (Anonymous; [@b0145]) or estimated using GastroPlus and ADMET predictor and are summarized in [Table 1](#t0005){ref-type="table"}. The model (ACAT) was used to simulate and foresee THQ absorption in the small intestine. A rat model of fasting physiology was selected and an optimized log D model was applied for determining the absorption scaling factors for the intestinal compartments. This model was used to fit the simulated PK profiles to the observed PK profiles after administration of 5 mg/kg I.V. and 20 mg/kg P.O. of THQ to male and female rats. Then, the model was used to predict the plasma profile after administration of multiple P.O. doses in both males and females.Table 1GastroPlus simulation inputs model parameters for thymoquinone (THQ).ParameterValueMethods/ReferenceMolecular weight (g/mol)164.2(Anonymous)Log P (at pH 7.4)2.2(Anonymous)pKa6.8Estimated by ADMET predictorSolubility (mg/ml)0.67([@b0145])Particle size (μm)25Default valueEffective permeability (10^−5^ cm/s)6.45Estimated by GastroPlus®*f*u~p~0.41Estimated by GastroPlus®Blood: Plasma ratio1.15Estimated by GastroPlus®[^1][^2]

2.5. Statistical analysis {#s0035}
-------------------------

The data are expressed as mean with standard error (SEM). The significance of the data was calculated by applying student T-test using Graph Pad Prism version 6 for Windows (Graph Pad Software, CA, USA). A *p* value of \<0.05 was considered significant.

3. Results and discussion {#s0040}
=========================

THQ at the I.V. dose of 5 mg/kg and P.O. dose of 20 mg/kg was well tolerated by all animals in the study. The analytical method used was successful in quantifying the plasma concentration of THQ up to 24 h. The plasma concentration--time curves of THQ following P.O. administration of 20 mg/kg to male and female rats as a single dose are shown in [Fig. 2](#f0010){ref-type="fig"}. Depicts the plasma concentration--time curves of THQ following I.V. administration (5 mg/kg) to male and female rats as a single dose. The plasma concentration following the P.O. administration increased swiftly, reaching maximum level at 2 h after dosing. The THQ pharmacokinetic parameters calculated using the non-compartmental analysis for both male and female rats are presented in [Tables 2](#t0010){ref-type="table"} for I.V. and P.O. treatment, respectively. The estimated absolute bioavailability of THQ was 0.58 in males and 0.57 in females. The C~max~ following I.V. and P.O. administration was slightly higher (i.e., ∼12--14%) in female than male rats. Upon the P.O. dosing, the C~max~ in males was 4.52 ± 0.092 μg/ml, while it was 5.23 ± 0.154 μg/ml in females (*p* = 0.002). THQ C~max~ post I.V. administration in male and female rats was 8.36 ± 0.132 μg/ml and 9.51 ± 0.158 μg/ml, respectively (*p* = 0.550). Similarly, the AUC~0-∞~ was ∼ 8% greater in females than in males (43.63 ± 0.953 μg.h/ml *vs.* 47.38 ± 0.821 μg.h/ml; *p* = 0.014) after P.O. dosing.Fig. 2Plasma concentration--time curves following P.O. administration (20 mg/kg) and I.V. administration (5 mg/kg) of a single thymoquinone (THQ) dose to male and female rats. Each value is expressed as mean ± SEM (n = 6); data points are connected by a trend line.Table 2Non-compartmental pharmacokinetic parameters of thymoquinone (THQ) after intravenous (I.V.) and P.O. administration in rats (n = 6).Parameter UnitI.V. dose 5 mg/kgp-valueP.O. 20 mg/kgp-valueMale\
Average ± SEMFemale\
Average ± SEMMale\
Average ± SEMFemale\
Average ± SEMλ~z~ (1/h)0.47 ± 0.0420.51 ± 0.0450.5510.07 ± 0.0040.07 ± 0.0080.664T~1/2~ (h)1.51 ± 0.1411.40 ± 0.1330.6109.52 ± 0.5729.43 ± 1.1130.947T~max~ (h)0.10 ± 0.0350.08 ± 0.0000.3402.00 ± 0.0002.00 ± 0.0001.000C~max~ (μg/ml)8.36 ± 0.1329.51 ± 0.1580.5504.52 ± 0.0925.23 ± 0.1540.002AUC~0-t~ (μg.h/ml)17.30 ± 0.75119.36 ± 0.7720.08634.27 ± 0.61138.04 ± 1.1050.013AUC~0-∞~ (μg.h/ml)18.77 ± 0.73020.73 ± 0.7630.09243.63 ± 0.95347.38 ± 0.8210.014AUMC~0-∞~ (μg.h^2^/ml)45.27 ± 1.76947.98 ± 1.9610.328631.33 ± 31.861657.66 ± 54.8130.686MRT~0-∞~ (h)2.41 ± 0.0812.31 ± 0.0530.31014.43 ± 0.48613.85 ± 1.0490.629Vz (ml/kg)584.60 ± 63.11492.19 ± 51.940.2816279.96 ± 284.625736.27 ± 639.040.455Cl (ml/h/kg)268.35 ± 10.47242.80 ± 9.360.092459.42 ± 9.75422.76 ± 7.440.014Vss (ml/kg)650.37 ± 38.91562.75 ± 27.770.100------

To further assess the effect of gender difference on the pharmacokinetics of THQ, we performed modeling and simulation of P.O. multiple doses to obtain steady-state parameters. The pharmacokinetics and disposition parameters obtained from *in vivo* studies and other parameters (such as permeability and solubility) predicted by GastroPlus program were used to form the simulation model, and absorption in intestines was imitated by using the ACAT model. The disposition and physicochemical parameters predicted were incorporated to establish the model. Finally, simulation trials of plasma concentration *vs.* time profiles for THQ using the disposition parameters predicted were performed for 5 mg/kg I.V. and 20 mg/kg P.O dosing. The trials stood effectively able to predict the THQ pharmacokinetic profiles rats. Analogy of the simulation outcomes with the experimental plasma pharmacokinetic profiles in male and female rats is presented in [Fig. 3](#f0015){ref-type="fig"}, respectively. The pharmacokinetic profiles predicted were analogous to the profiles observed, and goodness-of-fit was tested by comparing the experimental data with the predicted data at similar points. The correlation coefficient was greater than 0.85 for all doses. This model was also able to generate accurate estimates for the disposition parameters in male and female rats. [Table 3](#t0015){ref-type="table"} and [Fig. 3](#f0015){ref-type="fig"} show predicted plasma profiles and pharmacokinetic parameters (AUC~0-t~, AUC~0-∞~, C~max~, and T~max~), which were analogous to those observed experimentally at different doses of THQ. In addition, [Table 4](#t0020){ref-type="table"} and [Fig. 4](#f0020){ref-type="fig"} illustrate predicted plasma profile, C~max~, C~min~, C~ave~, AUC~ss,~ and clearance (Cl) at steady state for 20 mg/kg multiple P.O. doses of THQ every 8 h, 12, and 24 h in male and female rats.Fig. 3Simulated data and observed plasma profiles after 5 mg/kg I.V. administration (A) and 20 mg/kg P.O. administration (B) of thymoquinone (THQ) in male and female rats. The symbols represent the observed data and solid line represents the predicted data.Table 3Model predicted and observed parameters of thymoquinone (THQ) after administration of 5 mg/kg I.V. and 20 mg/kg P.O. in male and female rats and model predicted parameters of THQ at steady state for 20 mg/kg P.O. dose administered every 8, 12, and 24 h in male and female rats.PK parameterI.V. administrationP.O. administrationPredictedObservedPre/ObsPredictedObservedPre/ObsMale rats (n = 6)C~max~ (µg/ml)9.4028.3060.8834.3014.5080.961T~max~ (h)0.0810.0821.0001.7632.0000.882AUC~0-t~ (µg·h/ml)16.80217.3080.97130.80134.2040.906AUC~0-∞~ (µg·h/ml)19.30518.5041.04275.10764.8021.154  Female rats (n = 6)C~max~ (µg/ml)8.8039.2040.9645.1055.2020.982T~max~ (h)0.0810.0821.0001.7782.0000.881AUC~0-t~ (µg·h/ml)20.70221.2060.98136.50538.1060.951AUC~0-∞~ (µg·h/ml)23.30522.1021.05372.70262.1061.178Table 4Predicted steady state pharmacokinetic parameters of thymoquinone (THQ) for 20 mg/kg P.O. dose administered every 8, 12, and 24 h in male and female rats.PK parameterMale rats (n = 6)Female rats (n = 6)8 h12 h24 h8 h12 h24 hC~max~ (µg/ml)11.4028.8036.30411.7049.2036.903C~min\ (~µg/ml)7.5014.7042.1026.9034.3041.802C~ave~ (µg/ml)8.2045.9083.2038.3045.8023.109AUC~ss~ (µg·h/ml)65.30270.50276.10166.50669.90173.202Cl (ml/h/kg)310.01281.00262.09301.05297.14273.26Fig. 4Predicted plasma profiles of thymoquinone (THQ) for multiple P.O. administration of 20 mg/kg in male and female rats every 24 h (A), 12 h (B), and 8 h (C).

Previous studies have reported gender-related differences in drug disposition of some compounds. For example, significant gender-dependent differences in veratramine pharmacokinetics following P.O. administration were reported in rats, wherein the absolute bioavailability in males was much higher than that in females ([@b0110]). Diosbulbin B was also shown to have better absorption in female rats than in male rats after P.O. administration ([@b0160]). Interestingly, females have low levels of CYP3A, which contribute significantly to the first-pass metabolism ([@b0085]). The results of the present study indicate that THQ clearance slightly differs between male and female rats after a single dose. Irregularity in intestinal expression of P450 enzymes and gut transport of drugs such as p-glycoprotein and MDR-1 could explain the gender differences in plasma drug concentrations ([@b0100]). Hepatic clearance of THQ may also be less in female rats due to variations in cardiac output.

The sex-specific cytochrome P450s CYP2C11, 13 and CYP3A2 are expressed more in males as compared to females, whereas CYP2C12 is found more in females ([@b0050], [@b0080], [@b0095]). Each species has a significant gender difference in plasma clearance ([@b0155]). The higher CL in the male rats is believed to be caused by the higher metabolism of thymoquinone than in female rats. It is remarkable to note that equally phase I and phase II metabolism can determine gender-based differences ([@b0050]). Female rats had a lower Cl rate than the male rats. Thus, these differences (gender-based) in animals appear in increased Cl; in male rats, Cl decreased when equated to the Cl of female rats. Following the I.V. administration, the drug directly enters the systemic circulation, avoiding the first-pass metabolism in the intestinal wall and in the liver. Therefore, gender-dependent pharmacokinetics of any drug after different routes of administrations (i.e., I.V. *vs.* P.O.) is considered to be mainly due to variations in the first-pass metabolism. The volume of distribution (Vss) of THQ was slightly larger in males compared with females (∼14%). THQ is a lipophilic compound, which is known to be highly protein bound ([@b0030]). Therefore, the observed gender-based THQ pharmacokinetic could be explained by variations in drug clearance and/or volume of distribution, which may result in altered measured plasma drug concentrations between the two genders.

Many contributing parameters are compulsory to aid the absorption and disposition predictions of a drug after oral administration. As the physicochemical properties and dosage, the form of a drug, such as diffusivity, lipophilicity and solubility at different pH conditions are vital for predicting the solublization and dissolution of the drug in the gastrointestinal tract and the subsequent diffusion across the intestines ([@b0005]). These parameters were successfully used to predict the steady state pharmacokinetic parameters of THQ in male and female rats following 20 mg/kg P.O. dose administered every 8, 12, and 24 h. The findings demonstrated similar PK parameters at steady state in males and females does not seem to play a significant role in thymoquinone disposition.

4. Conclusion {#s0045}
=============

In conclusion, variations in metabolic capacity and volumes of distribution may explain this small gender difference in THQ pharmacokinetics following the administration of a single dose in a male and female rat model. However, simulations of steady state concentrations demonstrated comparable predicted PK parameters of THQ in both gender. Further studies are warranted to verify the gender similarity of THQ pharmacokinetics in humans for a possible future clinical use.
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